ANB Bank’s BridgeBio Pharma BBIO Stock Holding History

ANB Bank’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,838	Closed	-$211K	–	125
2026 Q2	$211K	Sell	2,838 -2	-0.1%	-$140	0.08%	126
2026 Q1	$211K	Buy	+2,840	New	+$206K	0.09%	126

Other funds holding BBIO

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Planning Strategies Lancaster, Pennsylvania $169M AUM

ANB Bank's BBIO Position: Q3 2026 in Review

ANB Bank sold out of BridgeBio Pharma (BBIO) in Q3 2026, closing a stake of 2,838 shares — an estimated $211K sold.

ANB Bank first reported a position in BBIO in Q1 2026 and held it in 2 quarters. The position peaked at $211K in Q2 2026. 12 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

ANB Bank reported no remaining BridgeBio Pharma position as of Q3 2026 after selling out during the quarter.
ANB Bank sold 2,838 BridgeBio Pharma shares in Q3 2026, an estimated $211K.
ANB Bank first reported a position in BridgeBio Pharma in Q1 2026 and held it in 2 quarters.
ANB Bank's BridgeBio Pharma position peaked at $211K in Q2 2026.
12 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on ANB Bank's 13F filing for Q3 2026, filed 9 Oct 2026.